Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue
Mandate

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue

November 12, 2020 Capital Markets and Public M&A

Vinge has advised Pareto Securities in its capacity as Sole Manager and Bookrunner in connection with a directed share issue in the pharmaceutical company Xbrane Bipharma, whereby Xbrane Biopharma receives gross proceeds of approximately SEK 200 million.

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process. The purpose of the share issue was, inter alia, to carry out a capital raise in a timely and cost-effective manner, further diversifying and strengthening Xbrane Biopharma´s shareholder base, as well as finance the continued development of Xbrane Biopharma´s product portfolio, including finalization of development and the regulatory process regarding Xlucane.

Vinge’s team has consisted of Jesper Schönbeck, Linnéa Sellström, Anders Sundin Lundberg and Lisa Malmborg.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025